Idhifa OverviewEnasidenib (previously AG-221 and CC-90007) is an experimental drug in development for treatment of cancer. It is a small molecule inhibitor of IDH2 (isocitrate dehydrogenase 2). It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The FDA granted fast track designation and orphan drug status for acute myeloid leukemia in 2014. It gained FDA approval in August 2017 for acute myeloid leukemia (AML) in patients with specific mutations of the isocitrat...
Read more Idhifa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enasidenib
Recent Idhifa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 100mg, 50mg
NDC Database Records for Idhifa: (2 results)Sorted by National Drug Code
- 59572-705 Idhifa 50 mg Oral Tablet, Film Coated by Celgene Corporation
- 59572-710 Idhifa 100 mg Oral Tablet, Film Coated by Celgene Corporation